In view of evidence indicating significant involvement of the insulin-like growth factor (IGF) system in the pathogenesis of prostate cancer, we measured serum IGF-I and IGF-binding protein-3 (IGFBP-3) in men with benign prostatic hyperplasia (BPH; n ϭ 75) or prostatic carcinoma (CaP; n ϭ 84). The age-matched patient populations were selected to have circulating prostate-specific antigen (PSA), the most reliable predictor of CaP, in the overlapping diagnostic gray zone range of approximately 4 -10 g/L. Of particular interest was investigation of intact, fragment, and total IGFBP-3 levels in relation to PSA, which is also a well established IGFBP-3 protease. Among the key findings were significantly higher IGF-I and intact IGFBP-3 levels in CaP vs. BPH (P Ͻ 0.001), whereas changes in fragment and total IGFBP-3 were statistically insignificant. As expected, total PSA levels were similar in the two groups of patients (P ϭ 0.173), whereas free PSA levels were significantly lower in those with CaP (P Ͻ 0.001). IGF-I and IGFBP-3 (intact and total) correlated significantly (P ϭ 0.024 to Ͻ0.001) and inversely (r ϭ Ϫ0.26 to Ϫ0.35) with free PSA in BPH, but not in CaP, and no correlations were found in comparisons involving total PSA. Statistical analysis of the various markers and their combinations indicated enhanced performance of IGF-I/free PSA [receiver operating characteristics area under the curve (AUC) ϭ 0.728] and intact IGFBP-3/free PSA (AUC ϭ 0.737) ratios in discriminating between BPH and CaP compared with the currently used free/total PSA ratio (AUC ϭ 0.689). Multivariate logistic regression models confirmed the observed relationships and identified IGF-I/free PSA and intact IGFBP-3/free PSA as independent factors in predicting the presence of CaP. We conclude that increases in IGF-I and intact IGFBP-3 levels are positively associated with the presence of CaP in this group of patients with low to moderately elevated PSA, and that their measurements in relation to PSA may help improve diagnostic discrimination between BPH and prostate cancer. (J Clin Endocrinol Metab 86: 694 -699, 2001) 
I NSULIN-LIKE GROWTH factors I and II (IGF-I and -II) are
mitogenic and antiapoptotic agents produced primarily by the liver and locally by a wide variety of tissues. IGFs circulate mostly complexed with IGF-binding protein-3 (IGFBP-3), which in association with the acid-labile subunit forms an approximately 150-kDa ternary protein complex (1) (2) (3) (4) . Under normal conditions, nearly all of the circulating IGFs remain ternary complexed (ϳ75-80%), and smaller proportions (ϳ20 -25%) are associated with the low molecular mass IGFBPs (IGFBP-1, IGFBP-2, IGFBP-4, IGFBP-5, and IGFBP-6) or exist (ϳ1%) in the free form (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) .
Dysregulation and/or overexpression of the IGF system have long been implicated in the etiology of both benign and malignant proliferative disorders (3, 4, (15) (16) (17) (18) (19) . Malignant cells of various origins have been shown to express various components of the IGF system (3, 4, 11-13, 18 -22) , and increased IGF levels, as seen in acromegaly, have been found in association with benign prostatic hyperplasia (BPH) (23, 24) and colonic tumors (25, 26) . A high level of circulating IGF-I has been more recently identified as a risk factor for the development of prostate, breast, and lung cancers (27) (28) (29) (30) , whereas overexpression of both IGF-I and IGF-II has been linked to colorectal cancers (31) . In prostate, both benign and malignant cells have been found to express IGFs, IGFBPs, and their respective receptors (18, 23) . IGF-I has been shown to promote prostate cell growth, whereas prostate-specific antigen (PSA) has been identified as an IGFBP-3 protease, presumably capable of augmenting tissue access to the IGF peptides (18, 23, 32) .
In men over 50 yr of age, cancer of the prostate (CaP) and BPH are among the most commonly diagnosed malignant and benign proliferative disorders, respectively (33) . However, the serum level of PSA, the most reliable predictor of CaP available to date, is also increased in BPH, resulting in a diagnostic gray zone for PSA values in the range of approximately 4 -10 g/L (34). In addition, a PSA level below 4 g/L does not necessarily indicate disease-free status, because a significant number of men with organ-confined CaP reportedly have normal serum PSA levels (35) . These significant limitations of PSA testing invariably result in a diagnostic dilemma, resulting in the loss of an opportunity for early cancer detection or avoidance of unnecessary surgical approaches to a readily treatable benign disorder, BPH. Although the ratio of free/total PSA levels in serum is significantly reduced in CaP, and its determination is now used to heighten the diagnostic accuracy of PSA testing (36, 37) , there is still a great need to further improve our ability to discriminate between BPH and prostate cancer (35) .
In view of the growing evidence describing association of the IGF system with cancer, we investigated differences in serum levels of IGF-I and levels of intact, fragment, and total IGFBP-3 in a group of patients with BPH and CaP. The age-matched patient populations were carefully selected to have total PSA in the diagnostic gray zone range. Because of the highly complex nature of IGF regulation (3, 4, 8, 11, 15) , particularly involving proteolysis (13, 14) , we postulated that investigation of IGF-I and IGFBP-3 variants in relation to free and total PSA levels might help identify better approaches for enhancing differential BPH/CaP detection.
Materials and Methods

Patient population and samples
Serum samples from 159 patients with BPH (75 men aged 55-75 yr; mean age Ϯ sd, 65.6 Ϯ 6.0) or prostate cancer (84 men aged 52-75 yr; mean age Ϯ sd, 64.8 Ϯ 6.2) were provided by Dr. E. P. Diamandis (Mount Sinai Hospital, Toronto, Canada). The samples were from patients with total PSA levels between 1.75-13.5 g/L and histologically confirmed disease status at biopsy. All specimens were residuals from routine or research tests samples and were stored frozen at Ϫ70 C, with fewer than 3 freeze/thaw cycles until analysis.
Analytical methods
IGF-I, intact IGFBP-3, fragment IGFBP-3, and total IGFBP-3 were assayed by ACTIVE enzyme-linked immunosorbent assay (ELISA) kits manufactured by Diagnostics Systems Laboratories, Inc. (Webster, TX). These assays are based on noncompetitive two-step ELISA involving a solid phase capture antibody and a soluble horseradish peroxidaselabeled detection antibody. The Diagnostics Systems Laboratories, Inc., nonextraction IGF-I ELISA is a modification of a previously described method involving acid-ethanol extraction (38) and has been demonstrated to yield results highly parallel to those of the extraction assay (27) . The IGF-I ELISA has a minimum detection limit of 1 ng/mL, a dynamic range of up to 600 ng/mL, and intra-and interassay coefficients of variation (CVs) of 4.5-8.6% and 3.3-6.8%, respectively. In the present study the average intraassay CV for IGF-I was 3.6%, which is well within the previously reported limits (27, 38, 39) .
The developmental rationale, analytical specifications, and performance characteristics of intact, fragment, and total IGFBP-3 ELISAs have been recently reported (40) . Briefly, the assays are based on a similar principle described for IGFBP-1 (41), involving a common capture antibody combined with three different detection antibodies for preferential detection of intact, fragment or total IGFBP-3 levels. The antibody selection was based on evaluation of a polyclonal and a panel of previously characterized anti-IGFBP-3 N-terminal, C-terminal, and midregion monoclonal antibodies (mAb) (42, 43) . In the assays, IGFBP-3 (intact and C-terminally truncated variants) is first captured by a mAb-recognizing epitope(s) in the N-terminal region of IGFBP-3. Next, the captured variants are quantified by a polyclonal Ab for measuring total IGFBP-3, a C-terminal specific mAb for measuring intact IGFBP-3, or a mAb with enhanced reactivity for proteolyzed IGFBP-3 for measuring fragmented IGFBP-3 (40) . As previously reported (40) , all three assays were calibrated against intact recombinant IGFBP-3, as individual assay calibration with intact, fragment, or combinations of intact and fragment IGFBP-3 would have been problematic, particularly with respect to consistency of preparations and standardization. The common calibration approach is the primary reason for the detection of comparatively higher immunoreactivity levels by fragment IGFBP-3 ELISA, which binds significantly better to proteolyzed IGFBP-3 than the intact molecule (40) . The IGFBP-3 ELISAs have dynamic ranges of 2-100 g/L, a lower detection limit of about 0.04 g/L, and intra-and interassay CVs of 3.4 -7.9% and 5-8.3%, respectively. In the present study the average intraassay CVs were 3.8% for intact, 3.3% for fragment, and 4.5% for total IGFBP-3 ELISAs.
Concentrations of free and total PSA were determined by Hybritech Tandem-R total and free (44) noncompetitive immunoradiometric methods (Hybritech, Inc., San Diego, CA).
Data analysis
The ELISA results were analyzed using the data reduction packages included in the Labsystems Multiskan microplate ELISA reader (Labsystems, Helsinki, Finland) with cubic spline (smoothed) curve fit.
The analysis of differences between IGF-I and IGFBP-3 concentrations in the two groups of subjects was performed with the nonparametric MannWhitney U test. Association of IGF-I and IGFBP-3 variants in serum with the other continuous parameters was examined using Spearman correlation. Receiver operating characteristics (ROC) curves were constructed by plotting sensitivity vs. (1 Ϫ specificity), and the areas under the ROC curves (AUC) were calculated. Univariate and multivariate unconditional logistic regression models were developed to evaluate the ability of IGF-I and IGFBP-3 levels to predict the presence of prostate cancer. The plots were established by StatView (Abacus Concepts, Inc., Berkeley, CA). The statistical analysis was performed by SigmaStat (SPSS, Inc., Chicago, IL), and SAS (SAS Institute, Inc., Cary, NC).
Results
IGF system components in BPH vs. CaP
In serum samples from a group of subjects with total PSA in the range of 1.75-13.5 g/L, IGF-I and intact IGFBP-3 levels were significantly higher in those with CaP than in those with BPH (P Ͻ 0.001), whereas changes in fragment and total IGFBP-3 were statistically insignificant (Table 1) . In these samples, the mean (Ϯsem) IGF-I and intact IGFBP-3 levels were 101.2 Ϯ 5.45 g/L (range, 10.9 -220) and 1.12 Ϯ 0.072 mg/L (range, 0.14 -2.71) in BPH and 126.6 Ϯ 4.89 g/L (range, 28 -218) and 1.48 Ϯ 0.068 mg/L (range, 0.32-2.78) in CaP patients. As expected (36), the total PSA levels were relatively similar, whereas the free PSA levels were significantly lower in CaP vs. BPH patients and were 0.757 Ϯ 0.049 g/L (range, 0.15-2.59) and 1.01 Ϯ 0.056 g/L (range, 0.31-3.15), respectively. In comparative correlation analysis (Spearman), neither IGF-I nor IGFBP-3 variants correlated significantly with the corresponding total or free PSA levels detected in CaP subjects. Similarly, IGF-I and IGFBP-3 variants did not demonstrate any significant correlation in relation to the total PSA levels in BPH (data not shown). In contrast, levels of IGF-I, intact IGFBP-3, and total IGFBP-3 in BPH patients showed negative correlation to the corresponding free PSA levels (r ϭ Ϫ0.26 to Ϫ0.33; P ϭ 0.024 to Ͻ0.001; Fig. 1 ). Interestingly, in both BPH and CaP patients, IGF-I levels correlated more tightly with intact (r ϭ 0.73-0.82) than with total (r ϭ 0.54 -0.70) IGFBP-3, whereas fragment IGFBP-3 was negatively related to IGF-I in BPH (r ϭ Ϫ0.36; P Ͻ 0.018) and not at all in CaP (r Ͻ0.1; P ϭ 0.4).
Calculated parameters
The inverse relation of IGF-I and intact IGFBP-3 vs. free PSA prompted evaluation of various concentration ratios for their cancer-discriminating ability. Among various possibilities, ratios of IGF-I/free PSA, intact IGFBP-3/free PSA, (IGF-I/total IGFBP-3)/free PSA, (intact IGFBP-3/total IGFBP-3)/free PSA, and (IGF-I plus intact IGFBP-3)/free PSA were most discriminative. For the above ratios, the median values were significantly different in BPH vs. CaP subjects and were 94.91 and 185, 0.85 and 2.09, 56.26 and 82.4, 0.489 and 0.938, and 0.978 and 2.361, respectively. As previously reported (36, 37) , the median free/total PSA ratio was lower in CaP than in BPH subjects (0.144 and 0.202, respectively). Although the observed differences were all highly significant (P Ͻ 0.001), the increases in the median values of the new parameters in Cap vs. BPH patients ranged from 1.46-fold (for IGF-I/total IGFBP-3)/free PSA ratio) to 2.46-fold (for intact IGFBP-3/free PSA). The free/total PSA ratio showed a relative change of only 1.39-fold. The median values and distributions of three of the ratios, IGF-I/free PSA, intact IGFBP-3/free PSA, and free/total PSA ratios, in patients with CaP vs. BPH are plotted in Fig. 2 .
ROC curves
In attempts to better define the cancer-differentiating potential of the measured and calculated parameters, ROC curves were constructed. In general, ratios demonstrated better discriminating powers than the individual variables. Ratios involving total PSA or fragment IGFBP-3 were the least discriminating, whereas those based on IGF-I, intact IGFBP-3, and free PSA were the most discriminating. Compared with the currently used free/total PSA (AUC, 0.689; 95% CI, 0.605-0.772), several permutations, particularly the ratios of intact IGFBP-3/free PSA (AUC, 0.737; 95% CI, 0.658 -0.816), and IGF-I/free PSA (AUC, 0.728; 95% CI, 0.649 -0.808) demonstrated better discriminative potential (Fig. 3) . The ratios of (intact IGFBP-3/total IGFBP-3)/free PSA (AUC, 0.747; 95% CI, 0.670 -0.824), (IGF-I plus intact IGFBP-3)/free PSA (AUC, 0.733; 95% CI, 0.653-0.812), and (IGF-I/total IGFBP-3)/free PSA (AUC, 0.725; 95% CI, 0.646 -0.805) also had potential, but involved measurement of a third variable. We examined other functions involving IGF-I, intact IGFBP-3, and free PSA (logarithmic ratios, difference), but none appeared promising. The comparative abilities of IGF-I/free PSA, intact IGFBP-3/free PSA, and free/total PSA ratio in differentiating between BPH and CaP at ROCselected cut-off points are summarized in Table 2 .
Univariate and multivariate analysis
We developed univariate and multivariate logistic regression models in attempts to further evaluate the cancer predictive value of the new determinants. As shown in Table 3 , using univariate analysis increased levels of IGF-I/free PSA and intact IGFB-3/free PSA ratios were found to be associated with increased probability for cancer. In multivariate analysis, IGF-I and IGFBP-3/free PSA-based variables were considered separately because of the strong correlation between these parameters as well as to show their separate relation to PSA measurement. These regression models were adjusted for IGF-I/free PSA or intact IGFBP-3/free PSA as well as for total PSA, free/total PSA, and age, all of which were considered continuous variables. These models of multivariate analysis identified both IGF-I/free PSA (crude odd ratio ϭ 2.8; 95% CI ϭ 1.72-4.6; P Ͻ 0.001) and intact IGFBP-3/free PSA (crude odd ratio ϭ 1.66; 95% CI ϭ 1.18 -2.34; P Ͻ 0.004) as independent factors in predicting the presence of CaP (Tables 4 and 5 ).
Discussion
We measured serum IGF-I and IGFBP-3 in a group of patients with BPH or CaP who had total PSA in the diagnostic gray zone range. Of major interest was investigation of intact, fragment, and total IGFBP-3 levels as indicators of cancer-associated proteolysis (40) , which has been long implicated in the etiology of various malignancies (13, 14, 45) . Among the key findings were identification of significantly higher levels of IGF-I and intact IGFBP-3 in CaP patients (P Ͻ 0.001), whereas changes in fragment and total IGFBP-3 were not statistically significant. Confirming previous observations (36, 37) , the free PSA levels were significantly lower in FIG. 2 . Distribution of various concentration ratios in BPH and CaP patients. Box plots showing distribution of IGF-I/free PSA (fPSA), intact IGFBP-3 (iBP3)/fPSA, and f/tPSA ratios in subjects with BPH and CaP. The median (centerline), 25th and 75th percentiles (lower and upper boundaries of the box, respectively), and the lowest and highest ratios within the 5th and 95th percentiles (lower and upper hatch lines, respectively) are shown. Analysis of differences was performed using the Mann-Whitney U test. Abbreviations are described in Table 1 . FIG. 3 . ROC curves. The comparative potentials of IGF-I/free PSA (fPSA) and intact IGFBP-3 (iIGFBP-3)/fPSA ratio relative to fPSA/ total PSA (tPSA) ratio in discriminating between BPH and CaP patients are shown. The corresponding AUC and CI are described in the text. Abbreviations are described in Table 1 . CaP patients (P Ͻ 0.001), although total PSA levels were similar in the two groups of matched patients (P ϭ 0.173).
In comparative correlation analysis, free PSA correlated significantly and inversely with levels of IGF-I and IGFBP-3 (intact and total) in BPH, but not in CaP, patients. In contrast, no correlations were found in comparisons involving total PSA. The latter may be expected, as the circulating PSA measured by the total assays (sum of free PSA plus PSA complexed with protease inhibitors) is considered enzymatically inactive (34, 46 -48) . However, the inverse relation of free PSA with IGF-I or IGFBP-3 in patients with BPH suggests that at least a proportion of the free PSA in BPH may circulate in the catalytically active form. Whether the reported trypsinlike activity of free PSA in BPH patients and its inability to efficiently complex with the protease inhibitor ␣ 1 -antichymotrypsin (48) is responsible for its observed inverse relation to IGF-I and IGFBP-3 remains to be investigated. We propose that reduced IGFBP-3 proteolysis, resulting in potential enhancement of IGF bioavailability at cellular levels, may be advantageous to tumor cell growth during early development, whereas the same mechanism might conversely protect the cells against the antiproliferative (apoptotic) properties of the bioactive IGFBP-3 peptides (8 -14) . In this context, we recently reported significant association of high IGFBP-3 in primary breast tumor extracts with unfavorable prognostic indicators of the disease (49) , and more recently found that total IGFBP-3 levels in breast nipple aspirate fluid were directly, and IGFBP-3 fragment levels were inversely related to breast cancer risk (50) .
Identification of markers with inverse relation in CaP (i.e. IGF-I and intact IGFBP-3 vs. free PSA) prompted examination of several concentration ratios and measurement permutations in relation to PSA. Among the various possibilities, ratios of total IGF-I/free PSA, intact IGFBP-3/free PSA, (IGF-I/total IGFBP-3)/free PSA, (intact IGFBP-3/total IGFBP-3)/ free PSA, and (IGF-I plus intact IGFBP-3)/free PSA appeared the most promising. By ROC analysis, determination of IGF-I/free PSA and intact IGFBP-3/free PSA demonstrated similar, if not better, discriminating potential than the free/total PSA ratio. Although several other permutations, notably ratio of (intact IGFBP-3/total IGFBP-3)/free PSA, showed better discriminative power, the relative improvement may not be significant enough to warrant inclusion of a third measurement component. However, the potential of growth factor/tumor marker combinations was further confirmed by multivariate analysis, which identified IGF-I/free PSA and intact IGFBP-3/free PSA as independent parameters for discriminating between BPH and CaP. As determined by the ROC analysis, at a cut-off ratio of less than 0.28 the free/total PSA ratio identified 95% of cancer patients with a specificity of 17%, confirming previous findings (36, 37) . This cut-off point yielded a positive predictive value (PPV) of 55%. On the other hand, the IGF-I/free PSA ratio and intact IGFBP-3/free PSA ratio at cut-off values of 51.4 and 0.5, respectively, identified 95% of the patients with a specificity of 20% and PPVs of 56% and 57%. Interestingly, the IGF-I/free PSA ratio at a cut-off value of 273 identified 29% of the cancer patients with a specificity of 95%, corresponding to a PPV of 85%. Intact IGFBP-3/free PSA at a cut-off value of 3.5 also detected 29% of patients with cancer with a specificity of 95% and a PPV of 85%. Thus, the findings of IGF-I/free PSA ratios greater than 273 and intact IGFBP-3/free PSA ratios greater than 3.5 are highly suggestive of the presence of CaP. As indicated in Table 2 , the cut-off points based on 95% specificity should be the preferred cut-off points, as cut-offs based on 95% sensitivity did not increase the PPV over the free/ total PSA ratio. The observation that IGF-I/free PSA or intact IGFBP-3/free PSA analysis appeared to compliment free/ total PSA testing is of significant interest and warrants further investigations of their relevance and potential diagnostic applications. We propose that development of diagnostic algorithms and/or mathematical models based on multivariate determinations of IGF-I, intact IGFBP-3, free and total PSA, as well as other pertinent clinical indicators may significantly improve the differential diagnosis of prostate cancer.
In summary, in a group of subjects with total PSA in the diagnostic gray zone range, we identified significantly higher IGF-I and intact IGFBP-3 levels in those with CaP than in those with BPH. Because IGF-I and IGFBP-3 did not correlate with PSA in CaP, but were inversely related to free PSA in BPH patients, we postulate that reduced proteolysis of IGFBP-3 might be linked to the pathogenesis of prostate cancer. Statistical analysis of the various biomarkers identified IGF-I/free PSA and intact IGFBP-3/free PSA ratios as potential new indicators of prostate cancer and indicated the need for further examination of this concept. 
